Kirk et al. DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma. Cell Rep Med 2024
Need more info on actual peptide<>TCR(?), write to authors